Black Cohosh and Climacteric Symptoms: Growing Knowledge about the Efficacy and Safety

Natural Product Communications

Volumn 2, Issue 10, 2007, Pages

  Bilia, Anna Rita ^a   Eterno, Federico ^a   Vincieri, Franco Francesco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Actaea racemosa; Black cohosh; Cimicifuga racemosa; climateric symptoms; efficacy; Ranunculaceae; safety

Indexed keywords

EID: 77954090236     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578X0700201013     Document Type: Article

References (140)

1. Rossow JE, Anderson GL, Rentice RL, LaCroix AZ, Kooperberg C, Stefanik ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of American Medical Association, 288, 321–333.
2. Murray MT, Pizzorno JE. (1999) Menopause. In: Textbook of Natural Medicine. Murray MT, Pizzorno JE (Eds). Churchill Livingstone, Kenmore, Washington, 1387–1396.
3. Barton BS. (1798) Collections for an Essay Towards a Material Medica of the United States. Way & Groff, Philadelphia, 9–11.
4. Rafinesque CS. (1928) Medical Flora or Manual of the Medical Botany of the United States of North America. Atkinson & Alexander, Philadelphia, 88–92.
5. Low Dog T, Powell KL, Weisman SM. (2003) Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief. Menopause, 10, 299–313.
6. Borrelli F, Izzo AA, Ernst E. (2003) Pharmacological effects of Cimicifuga racemosa. Life Sciences, 73, 1215–1229.
7. Blumenthal M. (2003) The ABC Clinical Guide to Herbs. American Botanical Council, Austin, Texas, 409.
8. Warnecke G. (1985) Beeinflussung klimakterischer beschwerden durch ein phytotherapeutikum: erfolgreiche therapie mit Cimicifugamonoextrakt. Die Medizinische Welt, 36, 871–874.
9. Stoll W. (1987) Phytotherapy influences atrophic vaginal epithelium: double-blind study-Cimicifuga vs. estrogenic substances. Therapeuticum, 1, 23–31.
10. Lehmann-Willenbrock E, Riedel HH. (1988) Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. Zentralblatt fur Gynakologie, 110, 611–618.
11. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D, Lo KM, Moore A, Rosenman PJ, Kaufman EL, Neugut AI, Grann VR. (2001) Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. Journal of Clinical Oncology, 19, 2739–2745.
12. Kronenberg F, Fugh-Berman A. (2002) Complementary and alternative medicine (CAM) for menopausal symptoms: a review of randomized control trails. Annals of Internal Medicine, 137, 805–813.
13. Lloyd JU, Lloyd CG. (1884) In Drugs and Medicines of North America. Vol. 1. Ranuncolaceae. JU & CG Lloyd, Cincinnati, 244–291.
14. Foster S. (1999) Black cohosh: Cimicifuga racemosa, a literature review. HerbalGram, 45, 35–50
15. Tantaquidgeon G. (1992) A Study of Delaware Indian Medicine Practice and Folk Beliefs. Pennsylvania Historical Commission, Harrisburg, 28–32.
16. Herrick JW. (1977) Iroquois Medical Botany. Ann Arbor: University Microfilms International, 320–321.
17. Hamel PB, Chiltoskey MU. (1975) Cherokee Plants Their Uses — A 400 Year History. North Carolina, Herald Publishing, 30.
18. Speck FG. (1917) Medical Practice of the Northeastern Algonquians. Proceedings of the 19th International Congress of Americanists, 310–311.
19. Mahady GB, Fong HHS, Farnsworth NR. (2002) Rhizoma Cimicifuga racemosae. In: WHO Monographs on Selected Medicinal Plants, Volume II. World Health Organization, Geneva.
20. Felter HW, Lloyd JU. (1898) Cimicifuga (USP)–Cimicifuga. King's American dispensatory, web site: http://www.henriettesherbal.com/eclectic/kings/cimicifuga.html.
21. Liske E. (1998) Therapeutic efficacy and safety of Cimicifuga racemosa for gynecologic disorders. Advances in Therapy, 15, 45–53.
22. Panizzi L, Corsano S. (1962) Actein. I. Atti della accademia nazionale dei Lincei. Rendiconti, 32, 601–605.
23. Bedir E, Khan IA. (2000) Cimiracemoside A: a new cyclolanostanol xyloside from the rhizome of Cimicifuga racemosa. Chemical & Pharmaceutical Bulletin, 48, 425–427.
24. Bedir E, Khan IA. (2001) A new cyclolanostanol arabinoside from the rhizome of Cimicifuga racemosa. Die Pharmazie, 56, 268–269.
25. Shao Y, Harris A, Wang M, Zhang H, Cordell GA, Bowman M, Lemmo E. (2000) Triterpene glycosides from Cimicifuga racemosa. Journal of Natural Products, 63, 905–910.
26. Hamburger M, Wegner C, Benthin B. (2001) Cycloartane glycosides from Cimicifuga racemosa. Pharmaceutical and Pharmacological Letters, 11, 15–17.
27. Wende K, Mugge C, Thurow K, Schopke T, Lindequist U. (2001) Actaeaepoxide 3-O-β-D-xylopyranoside, a new cycloartane glycoside from the rhizomes of Actaea racemosa (Cimicifuga racemosa). Journal of Natural Products, 64, 986–989.
28. Chen SN, Fabricant DS, Lu ZZ, Fong HHS, Farnsworth NR. (2002) Cimiracemosides I-P, new 9,19-cyclolanostane triterpene glycosides from Cimicifuga racemosa. Journal of Natural Products, 65, 1391–1397.
29. Chen SN, Li WK, Fabricant DS, Santarsiero BD, Mesecar A, Fitzloff JF, Fong HHS, Farnsworth NR. (2002) Isolation, structure elucidation, and absolute configuration of 26-deoxyactein from Cimicifuga racemosa and clarification of nomenclature associated with 27-deoxyactein. Journal of Natural Products, 65, 601–605.
30. Watanabe K, Mimaki Y, Sakagami H, Sashida Y. (2002) Cycloartane glycosides from the rhizomes of Cimicifuga racemosa and their cytotoxic activities. Chemical & Pharmaceutical Bulletin, 50, 121–125.
31. Suntry Ltd. (1984) Sodium 3-(α-L-arabinopyranosyl)-16,23-dihydroxyolean-12-en-28-oate. Japan Kokai Tokkyo Koho, JP 59020298, Japan, 3.
32. Kruse SO, Lohning A, Pauli GF, Winterhoff H, Nahrstedt A. (1999) Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid. Planta Medica, 65, 763–764.
33. Burdette JE, Chen SN, Lu ZZ, Xu H, White BE, Fabricant DS, Liu J, Fong HHS, Farnsworth NR, Constantinou AI, Van Breemen RB, Pezzuto JM, Bolton JL (2002) Black cohosh (Cimicifuga racemosa L.) protects against menadione-induced DNA damage through scavenging of reactive oxygen species: bioassay-directed isolation and characterization of active principles. Journal of Agricultural and Food Chemistry, 50, 7022–7028.
34. Chen SN, Fabricant DS, Lu ZZ, Zhang HJ, Fong HHS, Farnsworth NR. (2002) Cimiracemates A–D, phenylpropanoid esters from the rhizomes of Cimicifuga racemosa. Phytochemistry, 61, 409–413.
35. He K, Pauli GF, Zheng B, Wang H, Bai N, Peng T, Roller M, Zheng Q. (2006) Cimicifuga species identification by high performance liquid chromatography–photodiode array/mass spectrometric/evaporative light scattering detection for quality control of black cohosh products. Journal of Chromatography A, 1112, 241–254.
36. Li W, Chen S, Fabricant D, Angerhofer CK, Fong HHS, Farnsworth NR, Fitzloff JF. (2002) High-performance liquid chromatographic analysis of Black Cohosh (Cimicifuga racemosa) constituents with in-line evaporative light scattering and photodiode array detection. Analytica Chimica Acta, 471, 61–75.
37. Nuntanakorn P, Jiang B, Einbond LS, Yang H, Kronenberg F, Weinstein IB, Kennelly EJ. (2006) Polyphenolic Constituents of Actaea racemosa, Journal of Natural Products, 69, 314–318.
38. Lai GF, Wang Y-F, Fan L-M, Cao J-X, Luo S-D. (2005) Triterpenoid glycoside from Cimicifuga racemosa. Journal of Asian Natural Products Research, 7, 695–699.
39. Jarry H, Harnischfeger G. (1985) Endocrine effects of constituents of Cimicifuga racemosa. 1. The effect on serum levels of pituitary hormones in ovariectomized rats. Planta Medica, 51, 46–49.
40. Struck D, Tegtmeier M, Harnischfeger G. (1997) Flavones in extracts of Cimicifuga racemosa. Planta Medica, 63, 289–290.
41. McCoy J, Kelly W. (1996) Survey of Cimicifuga racemosa for phytestrogenic flavonoids. Book of Abstracts of 212th ACS National Meeting. Orlando, FL: American Chemical Society, 10, 15.
42. Jarry H, Harnischfeger G, Duker E. (1985) Studies on endocrine effects of the contents of Cimicifuga racemosa 2. In vitro binding of compounds to estrogen receptors. Planta Medica, 51, 316–319.
43. Jarry H, Leonhardt S, Duls C, Popp M, Christoffel V, Spengler B, Theiling K, Wuttke W. (1999) Organ-specific effects of Cimicifuga racemosa in brain and uterus. Book of Abstracts of the 23rd International LOF-Symposium on Phyto-Estrogens, University of Gent, Belgium.
44. Duker EM, Kopanski L, Jarry H, Wuttke W. (1991) Effects of extracts from Cimicifuga racemosa on gnadotropin release in menopausal women and ovariectomized rats. Planta Medica, 57, 420–424.
45. th Annual Meeting of the Society for Medicinal Plant Researc h. Zürich. P1B/03
46. Kennelly EJ, Baggett S, Nuntanakorn P, Ososki AL, Mori SA, Duke J. (2002) Analysis of thirteen populations of black cohosh for formononetin. Phytomedicine, 9, 461–467
47. Harnischfeger G, Cillien N. (1996) Influence of Cimicifuga racemosa extract fractions on the proliferation of human carcinoma cells in vitro with regard to their estrogen receptor sensitivity. Book of Abstracts of the 44th Annual Congress of Georg August Universitat, Gottingen, Germany. P12: 40.
48. Eagon CL, Elm MS, Eagon PK. (1996) Estrogenicity of traditional Chinese and Western herbal remedies. Proceeding of the American Association for Cancer Research, 37, 284.
49. Zava DT, Dollbaum CM, Blen M. (1998) Estrogen and progestin bioactivity of foods, herbs, and spices. Proceeding of the Society of Experimental Biology and Medicine, 217, 369–378.
50. Liu J, Burdette JE, Xu H, Gu C, Van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL. (2001) Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. Journal Agricultural and Food Chemistry, 49, 2472–2479.
51. Jarry H, Metten M, Spengler B, Christoffel V, Wuttke W. (2003) In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas, 44, S31–S38.
52. rd International LOF-Symposium on Phyto-Estrogens, University of Gent, Belgium.
53. Burdette JE, Liu J, Chen SN. (2003) Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. Journal of Agriculture and Food Chemistry, 51, 5661–5670.
54. Nesselhut T, Schellhase C, Dietrich R, Kuhn W. (1993) Study on the proliferative potential of phytopharmacological agents with estrogen-like effect in breast cancer cells. Archive of Gynecology and Obstetrics, 254, 817–818.
55. Shanies DD, Shaikh N. (1999) Growth inhibition of human breast cancer cells by herbs and phytestrogens. Oncology Reports, 6, 1383–1387.
56. Freudenstein J, Bodinet C. (1999) Influence of an isopropanolic aqueous extract of Cimicifuga racemosa rhizoma on the proliferation of MCF-7 cells. Book of Abstracts of the 23rd International LOF-Symposium on Phyto-Estrogens, University of Gent, Belgium.
57. Bodinet C, Freudenstein J. (2002) Influence of Cimicifuga racemosa on the proliferation of estrogen receptor positive human breast cancer cells. Breast Cancer Research and Treatment, 76, 1–10.
58. Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. (2002) Antiestrogenic activities of Cimicifuga racemosa extracts. Journal of Steroidal Biochemistry and Molecular Biology, 80, 125–130.
59. Amato P, Christophe S, Mellon PL. (2002) Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause, 9, 145–150.
60. Winterhoff H, Butterweck V, Jarry H, Wuttke W. (2002) Pharmakologische und Klinische Untersuchungen zum Einsatz von Cimicifuga racemosa bei klimakterischen beschwerden. Wien Medicine Wochenschrift, 152, 360–363.
61. Guabe F, Pusch L, Kroll T, Wölfl S, Hamburger M. (2005) Effects of Cinmicifuga racemosa (L.) NUTT. on human breast cancer cell line MFC-7 determined by gene expression profiling. Book of Abstracts of the 53rd Annual Congress of the Society for Medicinal Plant Reasearch, SL044.
62. Einbond LS, Su T, Wu H-A, Friedman R, Wang X, Jiang B, Hagan T, Kennelly EJ, Kronenberg F, Weinstein IB. (2007) Gene expression analysis of the mechanisms whereby black cohosh inhibits human breast cancer cell growth. Anticancer Research, 27, 697–712.
63. Gizicky HV. (1944) Arzneipflanzen in ihren Beziehungen zum weiblichen Genitalsystem. Versuche an weissen ratten und mausen mit cimicifuga racemosa. Zeitschrift für die gesamte experimentelle Medizin, 113, 635–644.
64. Foldes J. (1959) The actions of an extract of Cimicifuga racemosa. Arzneimittelforschung, 13, 623–624.
65. Eagon PK, Tress NB, Ayer HA, Wiese JM, Henderson T, Elm MS, Eagon CL. (1999) Medicinal botanicals with hormonal activity. Proceeding of the American Association for Cancer Research, 40, 161–162.
66. Freudenstein J, Dasenbrock C, Nisslein T. (2000) Lack of promotion of estrogen dependent mammary gland tumors in vivo by an isopropanolic black cohosh extract. Phytomedicine, 7, 13–20.
67. Jensen NE, Zhao J, Andersen KP, Kristoffersen K. (1996) Cimicifuga and Melbrosia lack estrogenic effects in mice and rats. Maturitas, 25, 149–153.
68. Liu Z, Yang Z, Zhu M, Huo Z. (2001) Estrogenicity of black cohosh (Cimicifuga racemosa) and its effect on estrogen receptor level in human cancer MCF-7 cells. Wei Sheng Yan Jiu, 30, 77–80.
69. Eagon CL, Elm MS, Teepe AG, Eagon PK. (1997) Medicinal botanicals: Estrogenicity in rat uterus and liver. Proceeding of the American Association for Cancer Research, 38, 293.
70. Nisslein T, Freudenstein J. (2000) Effects of black cohosh on urinary bone markers and femoral density in an ovx-rat model. Osteoporosis International, Supplement 4, S40–S41.
71. Seidlovà-Wuttke D, Jarry H, Becker T, Christoffel V, Wuttke W. (2003) Pharmacology of Cimicifuga racemosa extract BNO1055 in rats: bone, fat and uterus. Maturitas, 44, S39–S50.
72. Wuttke W, Seidlovà-Wuttke D, Gorkow C. (2003) The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas, 44, S59–S65.
73. Wuttke W, Jarry H, Becker T, Schultens A, Christoffel V, Gorkow C, Seidlovà-Wuttke D. (2003) Phytestrogens: endocrine disrupters on replacement for hormone replacement therapy? Maturitas, 44, S9–S20.
74. Langfritz W. (1962) Beitrag zur therapie von regeltempo-anomalien und deren beigleiterscheinungen bei jungen Mädchen und jungen frauen. Medizinische Klinik, 57, 1497–9.
75. th Annual Meeting of the North American Menopause Society (NAMS). New York. Abstract No. 99.012.
76. Unknown. (2003) Cimicifugae rhizome Black cohosh. ESCOP Monographs, The Scientific Foundation for Herbal Medicinal products, second edition, Thieme, London, 79–91.
77. Schotten EW. (1958) Erfahrungen mit dem Cimicifuga-Präparat Remifemin. Der Landarzt, 34, 353–354.
78. Stefan H. (1959) Ein Beitrag zu den Erscheinungsformen und zur Therapie hormonal bedingter Biopathiesyndrome der Frau. Ringelheim Biologie Umschau, 14, 157–162.
79. Stieheler K. (1959) Über die Anwendung eines standardisierten Cimicifuga-Auszuges in der Ginäcologie. Aerztliche Praxis, 11, 916–917.
80. Brücker A. (1960) Beitrag zur Phytotherapie hormonaler störungen der Frau. Die Medizinische Welt, 44, 2331–2333.
81. Heizer H. (1960) Kritisches zur Cimicifuga-Therapie bei hormonalen Störungen der Frau. Medizinische Klinik, 55, 232–233.
82. Görlich N. (1962) Behandlung ovarieller Störungen in der Algemeinpraxis. Aerztliche Praxis, 14, 1742–1743
83. Schildge E. (1964) Beitrag zur Behandlung von prämenstruellen und klimakterischen Verstimmungs-und Depressions-Zuständen. Ringelheimer Biologie Umschau, 19, 18–22.
84. Starfinger W. (1960) Therapie mit östrogen-wirksamen pflanzenextrakten. Medizinische Heute, 9, 173–174.
85. Kesselkaul O. (1957) Über die Behandlung klimakterischer Beschwerden mit Remifemin. Medizinische Monatsschrift, 11, 87–88.
86. Lieberman S. (1998) A review of the effectiveness of Cimicifuga racemosa (black cohosh) for the symptoms of menopause. Journal Women's health, 7, 525–529.
87. Borrelli F, Ernst E. (2002) Cimicifuga racemosa: a systematic review of its clinical efficacy. European Journal of Clinical Pharmacology, 58, 235–241.
88. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. (2005) Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstetrics and gynecology, 105, 1074–83.
89. Frei-Kleiner S, SchaffnerW RahlfsVW, Bodmer C, Birkhauser M. (2005) Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas, 51, 397–404.
90. Nappi RE, Malavasi B, Brundu B, Facchinetti F. (2005) Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecological Endocrinology, 20, 30–35.
91. Wuttke W, Gorkow C, Seidlova-Wuttke D. (2006) Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: A double-blind, placebo-controlled, and conjugated estrogens-controlled study, Menopause, 13, 185–196.
92. Wuttke W, Raus K, Gorkow C. (2006) Efficacy and tolerability of the black cohosh (Actea racemosa) ethanolic extract BNO 1055 on climacteric complaints: a double-blind, placebo- and conjugated estrogens-controlled study. Maturitas, 55, 83–91.
93. Liske E, Hanggi W, Henneicke-von Zepelin HH, Boblitz N, Wustenberg P, Rahlfs VW. (2002) Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. Journal of Women's Health & Gender-based Medicine, 11, 163–74.
94. Vermes G, Banhidy F, Acs N. (2005) The effects of remifemin on subjective symptoms of menopause. Advances in therapy, 22, 148–54.
95. Pockaj BA, Loprinzi CL, Sloan JA. (2004) Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Investigation, 22, 515–21.
96. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. (2006) Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Annals of Internal Medicine, 145, 869–879.
97. Radowicki S, Skórzewska K, Rudnicka E, Szlendak-Sauer K, Wierzba W. (2006) Effectiveness and safety of the treatment of menopausal syndrome with Cimicifuga racemosa dry extract. Ginekologia Polska, 77, 678–83.
98. Rotem C, Kaplan B. (2007) Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecology and Endocrinology, 23, 117–22.
99. Bai W, Henneicke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z, Geng L, Hu L, Chunfeng J, Liske E. (2007) Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: A randomized, double blind, parallel-controlled study versus tibolone. Maturitas, article in press, corrected proof.
100. Hernandez Munoz G, Pluchino S. (2003) Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas, 44, S59–S65.
101. Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton D., Sloan JA, Lavasseur BI, Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH. (2006) Phase III Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Black Cohosh in the Management of Hot Flashes: NCCTG Trial N01CC. Journal of Clinical Oncology, 24, 2836–2841.
102. Huntley A, Ernst E. (2003) A systematic review of the safety of black cohosh. Menopause, 10, 58–64.
103. Mahady GB. (2005) Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treatments in Endocrinology, 4, 177–184.
104. Dugoua JJ, Seely D, Perri D, Koren G, Mills E. (2006) Safety and efficacy of black cohosh (Cimicifuga racemosa) during pregnancy and lactation. Canadian Journal of Clinical Pharmacology. Fall, 13, e257–261
105. Minciullo PL, Saija A, Patafi M, Marotta G, Ferlazzo B, Gangemi S. (2006) Muscle damage induced by black cohosh (Cimicifuga racemosa). Phytomedicine, 13, 115–118.
106. Meyer S, Vogt T, Obermann EC, Landythaler M, Karrel S. (2007) Cutaneous pseudolymphoma induced by Cimicifuga racemosa. Dermatology, 214, 94–96
107. Unknown. (2004) Black cohosh (Cimicifuga racemosa) and hepatotoxicity. MHRA. Current Problems in Pharmacovigilance, 30, 10.
108. Unknown. (2004) National Institutes of Health: Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda (MD). Web site: http://nccam.nih.gov/news/pastmeetings/blackcohosh_mtngsumm.htm
109. Unknown. (2005) EMEA: European Medicines Agency, Committee on herbal medicinal products (HPMC). Assesment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root) Doc Ref: EMEA/HPMC/83845/2005
110. Unknown. (2006) EMEA: European Medicines Agency, Committee on herbal medicinal products (HPMC). Assesment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root) Doc Ref: EMEA/HPMC/88766/2006.
111. Unknown. (2007) EMEA: European Medicines Agency, Committee on herbal medicinal products (HPMC). Assesment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root) Doc Ref: EMEA/HPMC/26959/2006.
112. Danan G, Benichou C. (1993) Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. Journal of Clinical Epidemiology, 46, 1323–1330.
113. Benichou C, Danan G, Flahault A. (1993) Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. Journal of Clinical Epidemiology, 46, 1331–36.
114. Whiting PW, Clouston A, Kerlin P. (2002) Black cohosh and other herbal remedies associated with acute hepatitis. Medical Journal of Australia, 177, 440–443.
115. Lontos S, Jones RM, Angus PW, Gow PJ. (2003) Acute liver failure associated with the use of herbal preparations containing black cohosh. Medical Journal of Australia, 179, 390–391.
116. Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. (2004) Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause, 11, 575–577.
117. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. (2005) Fulminant Liver Failure Associated with the Use of Black Cohosh. Digestive Diseases and Sciences, 50, 538–539.
118. Lynch CR, Folkers ME, Hutson WR. (2006) Fulminant hepatic failure associated with the use of black cohosh: A case report. Liver Transplantation, 12, 989–992.
119. Unknown. (2006) Press release. 18 July 2006, http://www.mhra.gov.uk Medicines and Health care products Regulatory Agency.
120. Unknown. (2006). Cimicifuga racemosa (Black cohosh). Concerns of liver injury. WHO Pharmaceutical Newsletter, 4, 1.
121. Unknown. (2007) EMEA: European Medicines Agency, Committee on herbal medicinal products (HPMC). Assesment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root) Doc Ref: EMEA/HPMC/26958/2006.
122. Lupu R, Mehmi I, Atlas E, Tsai MS, Pisha E, Oketch-Rabah HA, Nuntanakorn P, Kennelly EJ, Kronenberg F. (2003) Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth. International Journal of Oncology, 23, 1407–12.
123. Nisslein T, Freudestein J. (2004) Concomitant administration of an isopropanolic extract of black cohosh and tamoxifen in the in vivo tumor model of implanted RUCA-I rat endometrial adenocarcinoma cells. Toxicology Letters, 150, 271–5
124. Freudenstein J, Dasenbrock C, Nisslein T. (2002) Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Research, 62, 3448–3452.
125. Raus K, Brucker C, Gorkow C, Wuttke W. (2006) First time proof of endometrial safety of the special Black cohosh extract (Actea racemosa or Cimicifuga racemosa extract) CR BNO 1055. Menopause, 13, 678–691.
126. Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B. (2007) An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause, 14, 89–96.
127. Davis VL, Jayo MJ, Hardy ML. (2003) Effects of black cohosh on mammary tumor development and progression in MMTV-neu transgenic mice. Proceedings of the American Association for Cancer Research, 44, R910.
128. Zepelin HH, Meden H, Kostev K, Schröder-Bernhardi D, Stammwitz U, Becher H. (2007) Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. International Journal of Clinical Pharmacology and Therapeutics, 45, 143–154.
129. Pepping J. (1999) Black cohosh, Cimicifuga racemosa. American Journal of Health-System Pharmacy, 56, 1400–1402.
130. Rockwell S, Liu Y, Higgins SA. (2005) Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Research and Treatment, 90, 233–239.
131. Tsukamoto S, Aburatani M, Ohta T. (2005) Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa). Evidenced-based Complementary and Alternative Medicine, 2, 223–226.
132. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. (2005) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clinical and Pharmacological Therapy, 77, 415–26.
133. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. (2006) Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. Journal of Clinical Pharmacology, 46, 201–13.
134. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S. (2006) Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metabolism and Disposition, 34, 69–74.
135. Blumenthal M, Busse W, Goldberg A (1998) Cimicifugae rizhome Black cohosh The Complete German Commission E Monographs Therapeutic Guide to Herbal Medicines, Integrative Medicine Communications, Boston, 90.
136. Unknown. (2002) American herbal pharmacopoeia and therapeutic compendium: black cohosh rhizome. Roy Upton Herbalist, editor. SantaCruz (CA): AHP.
137. Unknown. (2004) North American Menopause Society, Treatment of menopause-associated vasomotor symptoms position statement of the North American Menopause Society, Menopause, 11, 11–33.
138. Kligler B. (2003) Black cohosh. American Family Physician, 68, 114–6.
139. Thomsen M, Schmidt M. (2003) Hepatotoxicity from Cimicifuga racemosa? Recent Australian case report not sufficiently substantiated. Journal of Alternative and Complementary Medicine, 9, 337–340.
140. Thomsen M, Vitetta L, Sali A, Schmidt M. (2004) Acute liver failure associated with the use of herbal preparations containing black cohosh. The Medical Journal of Australia, 180, 598–599.